Vivani Medical, INC 10-Q quarterly reports

Vivani Medical, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued operating losses and a need for further financing, while also announcing progress on clinical trials and a proposed merger for its Cortigent subsidiary.

Vivani Medical reports Q1 2026 results, detailing progress in its Biopharm Division, continued operational expenses, and strategic considerations for its Cortigent subsidiary.

Vivani Medical reported increased net losses and significant cash burn in Q3 2025, while securing new capital and advancing its lead GLP-1 implant program, NPM-139, towards clinical trials in 2026.

Vivani Medical reported increased net losses in Q2 2025, while advancing its GLP-1 implant programs and progressing with the spin-off of its neurostimulation division.

Vivani Medical announces Q1 2025 financial results, highlighting ongoing clinical trial progress and strategic shifts in focus.

Vivani Medical's Q3 2024 report highlights progress in its GLP-1 implant program, including a redesigned clinical trial and positive preclinical data, while also showing a net loss for the quarter.

Vivani Medical reported its Q2 2024 financial results and provided updates on its GLP-1 implant programs, including the lifting of a clinical hold and a strategic shift towards obesity treatments.

Vivani Medical's Q1 2024 results show a net loss of $6.039 million, but the company secured $13.7 million in net proceeds from a securities purchase agreement.